University of Utah

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Utah sits in the top decile of US sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count).

818 total trials 138 currently recruiting 492 completed early-phase tilt top decile by trial count

University of Utah: 818 sponsored US clinical trials, 138 recruiting.

University of Utah sponsors 818 registered US clinical trials on ClinicalTrials.gov, 138 of them currently recruiting, and 492 completed. 45 of these trials are in Phase 3-4 (later-stage) and 268 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Low Back Pain, with 8 trials.

Top-decile sponsor footprint

University of Utah ranks in the top decile of sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 41/100

492 of 611 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

818 total, page 11 of 17

TERMINATED

Characterization of Human Autoantibody Titers After Central Nervous System Insult

NCT03089749

COMPLETED Phase 1

Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices

NCT02547766

COMPLETED

Preterm Infants and Nephrocalcinosis

NCT02438267

TERMINATED NA

Mind-Body Intervention for Veterans With PTSD

NCT02224989

COMPLETED Phase 2

Enoxaparin Metabolism in Reconstructive Surgery Patients

NCT02411292

COMPLETED

Bacterial Contamination of Operative Splash Basins

NCT02434510

COMPLETED NA

Cognitive Training and Practice Effects in Mild Cognitive Impairment

NCT02301546

TERMINATED Phase 2

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT02278783

COMPLETED NA

Management Strategies for Patients With Low Back Pain and Sciatica

NCT02391350

TERMINATED Phase 1

Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers

NCT02268825

COMPLETED NA

Preventing the Loss of Muscle and Function in Hospitalized Older Adults

NCT02566590

COMPLETED NA

Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

NCT02245217

COMPLETED NA

Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users

NCT02311478

TERMINATED Phase 1

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

NCT02200562

COMPLETED

HER Salt Lake Initiative

NCT02734199

COMPLETED

Outcomes Following Total Knee Arthroplasty

NCT02364011

COMPLETED Phase 1

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)

NCT02272270

COMPLETED NA

70 vs 110 Degree Side-cut Angles in Femtosecond LASIK

NCT03122535

COMPLETED NA

Patient Education for Patients With Back Pain Referred to Physical Therapy

NCT02648373

COMPLETED NA

Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study

NCT02155127

TERMINATED NA

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346

COMPLETED Phase 4

Loteprednol vs. Prednisolone and Fluorometholone

NCT03123614

COMPLETED Phase 1

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

NCT02286986

COMPLETED Phase 4

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417

TERMINATED Early Phase 1

Multimodal Pain Management Following Primary TKA

NCT02369523

COMPLETED

Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures

NCT02334618

COMPLETED Phase 2

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

NCT02199197

TERMINATED Phase 1

Regorafenib + Panitumumab for Colorectal Cancers

NCT02199223

COMPLETED Early Phase 1

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

NCT02097953

COMPLETED NA

Personalized Prenatal Care for Low-Risk Pregnancies Using Telemedicine

NCT01970436

TERMINATED Phase 2

Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

NCT02241720

COMPLETED

Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain

NCT02151513

COMPLETED NA

Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer

NCT02019303

COMPLETED NA

308nm Excimer Laser for Treatment of Fingernail Psoriasis

NCT02168933

COMPLETED Phase 4

BLIS - Breastfeeding Levonorgestrel IUD Study

NCT01990703

TERMINATED NA

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine

NCT01942486

TERMINATED NA

Two Anger Management Programs for Teens.

NCT02001246

COMPLETED Phase 1

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126

COMPLETED NA

Mind-Body Rehabilitative Program for Veterans With mTBI (Mild Traumatic Brain Injury)

NCT01975857

COMPLETED Phase 1

Muscle Afferent Feedback Effects in Patients With Heart Failure

NCT01919918

TERMINATED Phase 4

PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

NCT02520726

TERMINATED Phase 2

Probiotic (VSL #3) for Gulf War Illness

NCT02011542

COMPLETED Phase 2

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

NCT01832259

COMPLETED NA

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

NCT01805440

COMPLETED Phase 4

Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit

NCT01948505

COMPLETED NA

Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children

NCT02409277

TERMINATED Phase 1

Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies

NCT01818479

COMPLETED

Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception

NCT01963962

COMPLETED

Ultrasonographic Assessment of Carpal Tunnel Syndrome

NCT02196220

TERMINATED

Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel

NCT01957501

← Previous Page 11 of 17 Next →

Phase Distribution

PhaseTrial count
Phase 1 145
Phase 2 123
Phase 3 18
Phase 4 27

What is open in the University of Utah pipeline

138 recruiting of 818 indexed (17% open); 492 completed (60%).

Phase mix: 45 late (III/IV) vs 268 early (I/II) (early-phase heavy).

Top condition: Low Back Pain (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Utah: open-pipeline peers nationwide

Peers matched on 818 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of UtahUniversity of Texas Southwestern Medical CenterUniversity of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of HawaiiPenn State UniversityAdventHealthCSL Behring
University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 818 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this University of Utah page

818 registered trials is a research-attention snapshot, not an endorsement of University of Utah or any single study.

  • 138 of University of Utah's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Low Back Pain is the condition University of Utah studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Low Back Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Utah pipeline card: 818 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.